Category: 50998-17-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

EXAMPLE 121fert-Butyl 3-(quinoxalin-6-yl)benzylcarbamate6-Bromoquinoxaline (500 mg, 2.39 mmol), 3-(aminomethyl)phenylboronic acid hydrochloride (445 mg, 2.39 mmol), potassium phosphate (1000 mg, 4.78 mmol), water (3 mL), DME (13 mL) and Pd(PPh3)4 (277 mg, 0.24 mmol) were combined in a sealed tube and heated under microwave irradiation to 1400C for 1 h. Di-tert-butyl dicarbonate (545 mg, 2.50 mmol) was then added and the reaction mixture stirred at room temperature for 18 h. The organic layer was concentrated to dryness and purified by chromatography (SiO2, 20-100% EtOAc in petroleum ether) to give a yellow gum (232 mg). A sample (30 mg) was further purified by preparative HPLC to give the title compound (21.6 mg) as a clear solid. deltaH (CDCl3) 8.88 (IH, d, J 1.85 Hz), 8.85 (IH, d, J 1.86 Hz), 8.31 (IH, d, J 2.05 Hz), 8.18 (IH, d, J 8.73 Hz), 8.05 (IH, dd, J 8.74, 2.08 Hz), 7.67 (2H, d, J6.92 Hz), 7.49 (IH, t, J7.84 Hz), 7.37 (IH, d, J7.61 Hz), 4.93 (IH, s), 4.44 (2H, d, J5.95 Hz), 1.48 (9H, s). LCMS (ES+) 336 (M+H)+, RT 3.58 minutes {Method 2).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, vi) [(1R,3R)-3-(3-Chloro-phenylethynyl)-3-(4-methoxy-benzyloxy)-cyclohexyl]-quinoxalin-6-yl- amine: A solution of (1 R,3R)-3-(3-Chloro-phenylethynyl)-3-(4-methoxy-benzyloxy)- cyclohexylamine (34 mg), 6-bromoquinoxaline (23 mg), NaOt-Bu (13 mg), Pd2(dba)3 ‘ CHCI3 (1.9 mg) and BINAP (3.5 mg) in de-gassed toluene (2 ml) was stirred under Ar atmosphere for 1.5 h at 100. The mixture was distributed between cold 1 M Na2CO3 and EtOAc, the phases EPO separated, the aqueous phase ectracted with EtOAc, the combined organic phases dried over Na2SO4 and evaporated. Chromatography afforded 38 mf of the desired product (83%).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; NOVARTIS AG; NOVARTIS PHARMA GmbH; WO2006/114260; (2006); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To an oven-dried one-arm round bottom flask were added 6-bromoquinoxaline (10b) (216 mg,1.00 mmol), Pd(PPh3)2Cl2 (14.3 mg, 20.0 mumol), CuI (19.5 mg, 100 mumol) and anhydrous THF(2 mL) under argon atmosphere. The solution was bubbled with argon gas for 7 min to remove the dissolved gases. Then, trimethylsilylethyne (537 muL, 3.80 mmol) and Et3N (893 muL, 6.41mmol) were added sequentially, and the reaction mixture was stirred at rt for 14 h. Upon completion of the reaction, the reaction mixture was diluted with EtOAc (10 mL) and washed with water (2 ¡Á 7 mL) and brine (7 mL). The organic layer was dried over anhydrous MgSO4,filtered, and concentrated by rotary evaporation. Purification by column chromatography (10:1hexanes/EtOAc) yielded 11b (110 mg, 49%) as a brown solid., 50998-17-9

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Article; Jeong, Yunkyung; Lee, Jooyeon; Ryu, Jae-Sang; Bioorganic and Medicinal Chemistry; vol. 24; 9; (2016); p. 2114 – 2124;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

A mixture of N- (4- (methylsulfonyl) benzyl) -3, 4-dihydro-2H- 1 , 4-benzoxazine-7-carboxamide (0.028 g, 0.08 mmol) , 6- bromoquinoxaline (33 mg, 0.160 mmol), RuPhos Pd Gl (5.83 mg, 8.00 mumol), RuPhos (3.73 mg, 8.00 muetaalphaomicron) , NaOtBu (0.023 g, 0.240 mmol) and D E (1 mL) was heated at 130 C for 2 h under (3825) microwave irradiation. The reaction mixture was diluted with AcOEt (3 mL) and quenched with H20 (1 mL) , and stirred for 2 min. The organic layer was separated and then the aqueous layer was extracted with EtOAc (2 mL) . The combined organic layer was evaporated by blowing away with the air at 60 C. The residue was purified by preparative HPLC (Actus Triart C18, eluted with MeCN/10 itiM NH4HCO3 aq. 5:95?100:0). Pure fractions were combined and concentrated by blowing away with the air at 60C to afford the title compound (18.3 mg, 0.0368 mmol, 48%)., 50998-17-9

As the paragraph descriping shows that 50998-17-9 is playing an increasingly important role.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; YAMAMOTO, Satoshi; SHIRAI, Junya; KONO, Mitsunori; SHIOKAWA, Zenyu; YUKAWA, Tomoya; IMADA, Takashi; NEGORO, Nobuyuki; ODA, Tsuneo; SASAKI, Satoshi; NARA, Yoshi; SUZUKI, Shinkichi; SATO, Ayumu; ISHII, Naoki; SHIBUYA, Akito; NAKAGAWA, Yasuo; COLE, Derek; GIBSON, Tony; IVETAC, Anthony; SWANN, Steve; TYHONAS, John; (472 pag.)WO2018/30550; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, A solution of 6-bromo-quinoxaline (261 mg, 1.25 mmol), 1-ethoxyvinyltri-n-butyltin (0.47 mL, 1.4 mmol), palladium(II) acetate (16 mg) and tri-t-butylphosphonium tetrafluoroborate (41 mg) in anhydrous DMF (4 mL) under a nitrogen atmosphere was heated at 120 C. for 1 hr. The reaction mixture was cooled to ambient temperature and partitioned between ethyl acetate (25 mL) and H2O (10 mL). The organic extraction was washed with brine, dried (MgSO4), filtered, and concentrated. The concentrate was chromatographed on silica gel eluting with ethyl acetate:hexanes (1:1) to provide 110 mg of the title compound. 1H NMR (300 MHz, CDCl3) delta 2.79 (s, 3H), 8.18 (d, J=9 Hz, 1H), 8.36 (dd, J=9 Hz, J=3 Hz, 1H), 8.70 (d, J=3 Hz, 1H), 8.95 (s, 2H); MS (DCl/NH3) m/z 173 (M+H)+.

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; Altenbach, Robert J.; Black, Lawrence A.; Chang, Sou-jen; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Ku, Yi-yin; Liu, Huaqing; Lukin, Kirill A.; Nersesian, Diana L.; Pu, Yu-ming; Curtis, Michael P.; US2005/256309; (2005); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A mixture of methyl 4-bromobenzoate2a (100 mg, 0.465 mmol), methyl N-(tert-butoxycarbonyl)glycinate 3a (132 mg, 0.698 mmol), Pd2(dba)3 (8.5 mg,9.3 lmol), Xantphos (16 mg, 0.028 mmol), and cesium carbonate(303 mg, 0.930 mmol) was charged with dioxane (1.0 mL). Theresulting suspension was sparged with argon via subsurface bubblingfor 5 min, and the reaction mixture was sealed and stirredat 100 C for 12 h. The reaction was cooled to ambient temperature,diluted with EtOAc (20 mL), and filtered to remove the inorganicsalts. The filtrate was concentrated to an oil, then purified bycolumn chromatography on silica gel, eluting with an EtOAc/hexanesgradient (2-30%) to afford the desired product 4a as a colorlessgum (75% isolated yield). 1H NMR (500 MHz, DMSO-d6): d 7.90(d, J = 9.0 Hz, 2H), 7.40 (d, J = 8.5 Hz, 2H), 4.39 (s, 2H), 3.83 (s, 3H),3.68 (s, 3H), 1.37 (s, 9H). LRMS (ESI) calcd for C16H21NO6 (M+Na)+:346.1, found: 346.1., 50998-17-9

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Falcone, Danielle; Osimboni, Ekundayo; Guerin, David J.; Tetrahedron Letters; vol. 55; 16; (2014); p. 2646 – 2648;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, 6-Bromo quinoxaline (2.0 g, 9.5 mmcl) in toluene (20 mL) was degassed for 30 mm. To thissolution, 1-ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) and bis(triphenylphosphine)palladium dichloride (0.67 g, 0.95 mmol) were added at rt and stirred for 16 hours at 90 C. The reaction mixture was cooled to rt and filtered through celite. After evaporation of the solvent, 6 N HCI solution in water (20 mL) was added and the mixture was stirred for I hour at rt. It was concentrated and neutralized with sat. NaHCO3. The desired product wasextracted with DCM (100 mL), dried over Na2SO4 and concentrated. The crude productwas purified by column chromatography to afford the title compound (brown solid). 1H NMR(400 MHz, DMSO-d6): 6 9.06-9.04 (m, 2H), 8.70 (d, J=2.4 Hz, I H), 8.28 (t, J = 2.8 Hz, I H),8.16 (d, J = 11.6 Hz, IH), 2.97 (5, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.25 mm,99.06% (Max).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASCENEURON S. A.; QUATTROPANI, Anna; KULKARNI, Santosh, S.; GIRI, Awadut, Gajendra; (280 pag.)WO2017/144633; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

50998-17-9, 6-Bromoquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

50998-17-9, To a degassed stirred solution of 6-bromo quinoxaline (2.0 g, 9.50 mmol) in toluene (20 mL), 1- ethoxy vinyl tributyltin (3.8 g, 10.5 mmol) followed by Pd(PPh3)2CI2 (0.67 g, 0.95 mmol) were added at RT and stirred at 90 C overnight. After completion of the reaction (monitored by TLC), the reaction mixture was cooled to RT, filtered through celite and the obtained filtrate was evaporated under vacuum. To the resulting crude mixture, 6 N HCI solution (20 mL) was added and the mixture was stirred at RT for 1 h. The solution was neutralized with sat. NaHC03 and the aqueous layer was extracted with DCM (2 x 100 mL). The combined organic layer was dried over Na2S04 and concentrated under vacuum. The resulting crude material was purified by flash chromatography (Biotage Isolera, eluent: 30% EtOAc in hexane) to afford the title compound. Yield: 45% (800 mg, brown solid). 1H NMR (400 MHz, DMSO-tf6): delta 9.06-9.04 (m, 2H), 8.70 (d, J = 2.4 Hz, 1 H), 8.28 (dd, J = 8.8, 2.8 Hz, 1 H), 8.16 (d, J = 8.4 Hz, 1 H), 2.97 (s, 3H). LCMS: (Method A) 173 (M+H), Rt. 2.2 min, 99.1 % (Max).

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; ASCENEURON S.A.; QUATTROPANI, Anna; KULKARNI, Santosh S.; GIRI, Awadut Gajendra; (134 pag.)WO2019/37860; (2019); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.,50998-17-9

A solution containing 6-bromo-quinoxaline (417 mg, 2.0 mmol), 4-(4,4,5,5- tetramethyl-[1 ,3,2]dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert- butyl ester (600 mg, 1.94 mmol), tetrakis [triphenylphosphine] palladium (108 mg, 0.1 mmol) and sodium carbonate (2 M solution, 3 mL) in 5 ml_ of dioxane/ethanol/water (7:3:1 ) was heated at 160 C using microwave reactor for 15 minutes. After the reaction, ethylacetate was added and the mixture was filtered, washed with water. After concentration under vacuum, the product was purified using column chromatography (5% methanol in dichloromethane)

The synthetic route of 50998-17-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SCHERING CORPORATION; WO2008/156739; (2008); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.50998-17-9,6-Bromoquinoxaline,as a common compound, the synthetic route is as follows.

50998-17-9, To 6-bromo-quinoxaline (1 g) in acetonitrile (25 mL) was added propargyl alcohol (0.285 mL) and triethylamine (1.334 mL) followed by copper(I) iodide (10 mg) and bis(triphenylphosphine)palladium chloride (34 mg). The reaction mixture was stirred under nitrogen and then heated at 800C for 18h. The mixture was allowed to cool and then filtered. The filtrate was evaporated and then purified by chromatography on silica eluting with ethylacetate / isohexane (1 : 1 to 1 : 0) to afford the sub-titled compound as a solid (0.7 g).1H NMR (400 MHz, DMSO) I’ 8.97 (2H, dd), 8.13 (IH, d), 8.10 (IH, d), 7.84 (IH, dd), 5.45 (IH, t), 4.39 (2H, d).

50998-17-9 6-Bromoquinoxaline 610939, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; ARGENTA DISCOVERY LIMITED; ASTRAZENECA AB; WO2009/153536; (2009); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider